On October 8th, Guangdong Provincial Food and Drug Administration announced that Huawei’s “single-guide ECG blood pressure wrist device” was officially approved for production, and the trustees were GoerTek Inc. and Weifang Jingwei High-Tech Electronic Technology Co., Ltd.
In addition to the new wrist device, three other medical devices from Huawei have also entered the priority approval process, including an “ECG blood pressure recorder” to be worn on the wrist and an “ECG analysis system and arrhythmia analysis system”.
Earlier this May, He Gang, President of Huawei’s mobile phone product line, had posted on Weibo that the first Huawei smartwatch to measure blood pressure from the wrist had passed the necessary medical device registration test, and the next step would be to set up clinical trials with a view to launch a blood pressure monitoring Huawei smartwatch in the second half of this year.
On September 6th, Huawei also started the recruitment of blood pressure testers through its member App, taking precedence over those with a wrist circumference greater than 200mm and blood pressure higher than 140mm Hg.
ITHome.com reported that Huawei is currently developing wearable blood pressure measuring devices with a focus on home medical-grade high-precision blood pressure monitors. At the same time, the company has also collaborated with well-known domestic institutions to begin research on hypertension management which seeks to explore an innovative active health management system of blood pressure from screening to early intervention.
According to Huawei official, Huawei Medical has served more than 3,000 medical and health service institutions, providing the medical industry with a comprehensive, safe, simple, and future-oriented wireless network solution.